SLS · SELLAS Life Sciences Group, Inc.

Summary

SELLAS Life Sciences Group, Inc. received approximately $16.1 million in proceeds from the exercise of additional common stock warrants since January 8, 2026, bringing the total proceeds subsequent to December 31, 2025, to approximately $42.6 million. As of March 11, 2026, the Company had 179,536,724 shares of common stock outstanding.

Key takeaways

• Received $26.5 million from warrant exercises as of January 8, 2026
• Received additional $16.1 million from warrant exercises since January 8, 2026
• Total proceeds from warrant exercises subsequent to December 31, 2025: $42.6 million
• 179,536,724 shares of common stock outstanding as of March 11, 2026